微信公众号

官网二维码

中国癌症防治杂志 ›› 2025, Vol. 17 ›› Issue (5): 640-646.doi: 10.3969/j.issn.1674-5671.2025.05.16

• 综述 • 上一篇    下一篇

乳酸化修饰在肝细胞癌中的研究进展

  

  1. 川北医学院;遂宁市中心医院消化中心五病区
  • 出版日期:2025-10-25 发布日期:2025-12-03
  • 通讯作者: 奉镭 E-mail:fenglei822@163.com
  • 基金资助:
    四川省医学科研课题计划项目(S22028)

Research progress on lactylation in hepatocellular carcinoma


  • Online:2025-10-25 Published:2025-12-03

摘要: 肝细胞癌(hepatocellular carcinoma,HCC)是原发性肝癌的主要类型,多数患者确诊时已处于中晚期,预后较差。乳酸化修饰是一种由细胞代谢驱动的新型蛋白质翻译后修饰,通过修饰组蛋白及关键效应蛋白,在调控癌基因表达、驱动代谢重编程及塑造免疫抑制性肿瘤微环境等层面发挥关键作用。研究表明,乳酸化修饰在HCC的诊断、预后评估及靶向治疗中表现出重要潜力,抗乳酸化修饰调节与免疫治疗联用还可能进一步提高HCC的疗效。该修饰不仅可作为HCC诊断及预后预测的潜在生物标志物,还因其调控网络中的关键节点,为药物开发提供了富有前景的新靶点。本文总结了乳酸化修饰的形成和功能,其驱动HCC恶性进展的作用机制和在HCC诊断和治疗中的应用潜力。

关键词: 肝细胞癌, 乳酸化修饰, 代谢重编程, 肿瘤微环境, 治疗靶点

Abstract:  Hepatocellular carcinoma (HCC) is the predominant type of primary liver cancer, with the majority of  patients being diagnosed at intermediate to advanced stages, resulting in a poor prognosis. Lactylation, a novel post⁃translational modification (PTM) driven by cellular metabolism, plays a pivotal role in regulating oncogene expression, driving metabolic reprogramming, and shaping the immunosuppressive tumor microenvironment (TME) by modifying histones and key effector proteins. Research has demonstrated that lactylation exhibits significant potential in HCC diagnosis, prognostic assessment, and targeted therapy. The combination of anti⁃lactylation regulation and immunotherapy may further enhance the efficacy of HCC treatment. Lactylation serves not only as a potential biomarker for HCC diagnosis and prognosis prediction, but also provide promising new targets for drug development through its key nodes within the regulatory network. This review summarizes the generation and functions of lactylation, its mechanisms in driving HCC malignant progression, and its potential applications in HCC diagnosis and treatment.

Key words: Hepatocellular carcinoma, Lactylation, Metabolic reprogramming, Tumor microenvironment, Therapeutic target

中图分类号: 

  • R735.7